最近最经典中文mv字幕-最近韩国电影免费高清hd-最近的中文字幕大全免费-最近日韩中文字幕中文翻译歌词

您好，歡迎來(lái)到上海士研管理咨詢(xún)有限公司
產(chǎn)業(yè)峰會(huì) 演講局 專(zhuān)家智庫(kù)服務(wù) 峰會(huì)活動(dòng)服務(wù) 整合營(yíng)銷(xiāo)服務(wù)
  • 產(chǎn)業(yè)峰會(huì)：
    以專(zhuān)業(yè)團(tuán)隊(duì)對(duì)產(chǎn)業(yè)和市場(chǎng)客觀詳實(shí)地調(diào)研為前提，擁有戰(zhàn)略性、系統(tǒng)性、全球性的基因，匯集了領(lǐng)導(dǎo)者關(guān)注的熱點(diǎn)話(huà)題與領(lǐng)袖代表，為您提供“一站式”的對(duì)話(huà)、分享、社交平臺(tái)!
  • 演講局：
    致力于為全球企業(yè)和機(jī)構(gòu)提供主題演講家、高管大師班、董事會(huì)顧問(wèn)，每項(xiàng)服務(wù)都提供了一種更深入、更具互動(dòng)性的體驗(yàn)，尤其是針對(duì)較小的精選受眾和關(guān)鍵個(gè)人。我們擁有最具影響力的商業(yè)領(lǐng)袖和頂級(jí)專(zhuān)家的資源，他們是各自領(lǐng)域的最杰出的代表。我們的團(tuán)隊(duì)由經(jīng)驗(yàn)豐富的演講和活動(dòng)經(jīng)理組成，我們注重建立長(zhǎng)期而深入的伙伴關(guān)系。
  • 專(zhuān)家智庫(kù)服務(wù)：
    中國(guó)領(lǐng)先的行業(yè)專(zhuān)家知識(shí)信息服務(wù)供應(yīng)商，為需要專(zhuān)業(yè)洞見(jiàn)的商業(yè)決策者匹配具有一手經(jīng)驗(yàn)的行業(yè)專(zhuān)家，助力他們以更加明確的目標(biāo)和堅(jiān)定的信心做出決策。我們有60萬(wàn)余名專(zhuān)家顧問(wèn)遍布二十多個(gè)行業(yè)，而且每天還在增加！
  • 峰會(huì)活動(dòng)服務(wù)：
    致力于成為全球最專(zhuān)業(yè)的產(chǎn)業(yè)峰會(huì)活動(dòng)提供商，為企業(yè)和機(jī)構(gòu)的產(chǎn)業(yè)性峰會(huì)活動(dòng)提供一站式專(zhuān)業(yè)服務(wù)，包括調(diào)研策劃、定制邀請(qǐng)、營(yíng)銷(xiāo)推廣、運(yùn)營(yíng)組織、項(xiàng)目管理、直播與數(shù)字化會(huì)議等，每項(xiàng)服務(wù)都由經(jīng)驗(yàn)豐富的專(zhuān)業(yè)團(tuán)隊(duì)匹配長(zhǎng)期沉淀的產(chǎn)業(yè)資源予以卓越執(zhí)行，我們注重建立長(zhǎng)期而深入的伙伴關(guān)系。
  • 整合營(yíng)銷(xiāo)服務(wù)：
    致力于成為全球領(lǐng)先的2B營(yíng)銷(xiāo)服務(wù)機(jī)構(gòu)，聚焦產(chǎn)業(yè)高端活動(dòng)、內(nèi)容、渠道的建設(shè)與沉淀，為客戶(hù)提供一站式整合營(yíng)銷(xiāo)解決方案，助力企業(yè)線(xiàn)上線(xiàn)下獲客與品牌筑造。我們深信專(zhuān)業(yè)團(tuán)隊(duì)匹配產(chǎn)業(yè)資源帶來(lái)卓越執(zhí)行，我們注重建立長(zhǎng)期而深入的伙伴關(guān)系。
會(huì)議贊助商
7
2026 - 01 - 27
點(diǎn)擊次數(shù):
迪普深合以前沿的諾貝爾獎(jiǎng)“點(diǎn)擊化學(xué)（Click Chemistry）”技術(shù)為核心，是全球目前唯一的該技術(shù)的商業(yè)化實(shí)體。公司通過(guò)自主開(kāi)發(fā)的“模塊化的點(diǎn)擊化合物庫(kù)”構(gòu)建方法，突破傳統(tǒng)化學(xué)合成的局限，實(shí)現(xiàn)精準(zhǔn)、快速的超高通量合成，切實(shí)實(shí)現(xiàn)以用戶(hù)為中心，構(gòu)建專(zhuān)屬分子庫(kù)；并可直接用于活性篩選。公司正全力構(gòu)建全球領(lǐng)先的點(diǎn)擊化學(xué)分子砌塊庫(kù)，隨著這一點(diǎn)擊化合物庫(kù)的逐步建設(shè)與一個(gè)個(gè)運(yùn)用點(diǎn)擊化學(xué)技術(shù)的實(shí)例落地，公司正逐步成長(zhǎng)為藥物研發(fā)、化妝品、石化、農(nóng)藥及材料科學(xué)等領(lǐng)域的探索者與賦能者，為這些行業(yè)的合作伙伴提供從源頭分子的創(chuàng)新與結(jié)構(gòu)優(yōu)化，到關(guān)鍵技術(shù)的全方位支持；最終有望提高社會(huì)整體的科研、化工生產(chǎn)的效率。Core Technology and InnovationDeepSyn Pharmaceutical R&D（Shanghai）Co.,Ltd.(DeepSyn) centers its operations on the cutting-edge, Nobel Prize-winning "Click Chemistry" technology and is currently the world’s only commercial entity dedicated to this technology. Through its proprietary "modular click compound library" construction methodology, the company breaks through the constraints of traditional chemical synthesis. It achieves precise, rapid, and ultra-high-throughput synthesis, focusing on a user-centric approach to build exclusive molecular libraries that can be directly applied to activity screening.Industry Empowerment and VisionThe company is fully committed to establishing a world-leading library of click chemistry molecular building blocks. As this library is progressively developed and practical applications of click chemistry technology are realized, DeepSyn is evolving into an explorer and enabler in several key sectors:· Target Industries: These include pharmaceutical R&D, cosmetics, petrochemicals, pesticides, and materials science7.· Comprehensive Support: The company provides partners with full-spectrum assistance, from the innovation and structural optimization of source molecules to essential technical support.· Social Impact: These efforts are ultimately expected to enhance the overall efficiency of scientific research and industrial chemical production for society.
8
2026 - 01 - 27
點(diǎn)擊次數(shù):
成都先導(dǎo)藥物開(kāi)發(fā)股份有限公司（上海證券交易所股票代碼：688222.SH，股票名稱(chēng)：成都先導(dǎo)）致力于打造國(guó)際領(lǐng)先的創(chuàng)新型生物醫(yī)藥企業(yè)，總部位于中國(guó)成都，在英國(guó)劍橋、美國(guó)休斯頓設(shè)有子公司。公司聚焦小分子及核酸新藥的發(fā)現(xiàn)與優(yōu)化，著力打造了國(guó)際領(lǐng)先的DNA編碼化合物庫(kù)技術(shù)（DEL）平臺(tái)，并拓展了基于分子片段和三維結(jié)構(gòu)信息的藥物設(shè)計(jì)技術(shù)（FBDD/SBDD）、基于寡核苷酸的藥物研發(fā)技術(shù)（OBT）和靶向蛋白降解技術(shù)（TPD）的核心技術(shù)平臺(tái)；同時(shí)，公司正在建設(shè)DEL+AI+自動(dòng)化DMTA（設(shè)計(jì)-合成-測(cè)試-分析）分子優(yōu)化能力平臺(tái)，以期加速臨床前候選藥物發(fā)現(xiàn)及優(yōu)化過(guò)程。通過(guò)新藥研發(fā)服務(wù)、不同階段在研項(xiàng)目轉(zhuǎn)讓以及遠(yuǎn)期的藥物上市等多元化的商業(yè)模式，成都先導(dǎo)與全球數(shù)百家制藥公司、生物技術(shù)公司、化學(xué)公司、基金會(huì)以及科研機(jī)構(gòu)建立了合作。目前，公司有多個(gè)內(nèi)部新藥項(xiàng)目處于臨床及臨床前不同階段。About HitGen Inc.HitGen Inc. (SSE: 688222.SH), is a drug discovery research company headquartered in Chengdu, China, with subsidiaries in Cambridge, UK and Houston, USA. HitGen has established leading technology platforms to enable the discovery and optimization of small molecules and nucleic acid-based drugs. Our key technology platforms include world-leading DNA-encoded library technology (DEL), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), as well as the emerging technology platforms for oligonucleotide-based therapeutics (OBT), and targeted protein degradation technology (TPD). Meanwhile, we are developing a DEL+AI+ Automated DMTA (Design-Make-Test-Analyze) molecular optimization platform to accelerate the discovery and optimization process of preclinical candidate compounds. Through our diverse and flexible business models, we have built up collaboration partnerships with several hundred biopharmaceutical research organizations worldwide. HitGen has multiple programmes from early discovery to clinical trial stage.官網(wǎng)鏈接：https://www.hitgen.com/cn
9
2026 - 01 - 27
點(diǎn)擊次數(shù):
蛋白質(zhì)是生物功能的主要載體，如果能像基因測(cè)序一樣直接破譯蛋白的一級(jí)結(jié)構(gòu)，對(duì)了解生命活動(dòng)的分子機(jī)制具有重大意義。Rapid Novor一直致力于無(wú)需基因序列的蛋白從頭測(cè)序技術(shù)，是全球首個(gè)提供單克隆抗體自動(dòng)化測(cè)序服務(wù)的公司。目前Rapd Novor擁有全球最大的蛋白測(cè)序質(zhì)譜平臺(tái)，是蛋白從頭測(cè)序技術(shù)的領(lǐng)跑者。RapdNovor的蛋白從頭測(cè)序技術(shù)已被應(yīng)用于多發(fā)性骨髓瘤MRD監(jiān)測(cè)，可以直接對(duì)人血清高濃度單克隆免疫球蛋白進(jìn)行測(cè)序，并獲得美國(guó)CLIA臨床認(rèn)證。上海快序生物科技有限公司是加拿大Rapid Novor 的中國(guó)公司。快序生物在中國(guó)提供的服務(wù)包括:抗體測(cè)序，抗體發(fā)現(xiàn)，腫瘤新抗原鑒定服務(wù)等。Rapid Novor Shanghai Kuaixu Biotechnologies Co., Ltd. )has the world's leading de novo protein sequencing technologyand is commited to the applicationof this technolosy in the medical field. De novo sequencing is a technique that does not rely on existing DNA or protein database information and directlydetermines the amino acid sequence of proteins. Based on this technology. Rapid Novor(Kuaikxu) has established a new platform for antibody discovery andneoantigen identification. The antibody discovery platform can directly sequence antibody proteins in the serum ofimmunized animals or humans to obtainnatural antibody sequences, thereby significantly shortening the cycle of antibody drug development. However, drect sequencing of the MHC-bound peptidesegmentto obtain the actualpresented neoantigen sequence completely changes the previous discovery mode of neoantigens, which was mainly predicted bythe gene sequencing and algorthm. Rapid Novor (Kuaixu) has always been commited to developing the next generation of protein sequencing technology todecode the immune system and benefit human health.官網(wǎng)鏈接：https://www.kuaixu.com/
微信公眾號(hào)
領(lǐng)導(dǎo)者網(wǎng)絡(luò)APP
Copyright ?2005 - 2017上海士研管理咨詢(xún)有限公司
犀牛云提供企業(yè)云服務(wù)